The main highlights of 2023 AASLD Annual Meeting
<Hepatology Digest>: What are the main highlights of this Annual Meeting? Is it very different from the previous two ones？
How can patients perceive and actively manage MASLD on their own?
<Hepatology Digest>: How can patients perceive and actively manage MASLD on their own to alleviate the condition and avoid further deterioration?
Current treatment status and challenges for intermediate and advanced stage HCC
<Hepatology Digest>: What is the efficacy of current treatment strategies for intermediate and advanced stage HCC, and what are the challenges and limitations associated with them?
The mechanism of tumor microenvironment affecting the occurrence and development of HCC
<Hepatology Digest>: How does the tumor immune microenvironment affect the efficacy of precision HCC therapy?
The worldwide prevalence trend of MASLD
<Hepatology Digest>: What is the prevalence trend of MASLD globally? Are there specific regions or populations that are more affected and why?
IAS 2023 | South African study indicates that HIV male patients have a greater likelihood of achieving virological remission than females.
In the recent 12th International AIDS Society (IAS) HIV Science Conference (IAS 2023), a research study from South Africa found that, despite seldom adhering to antiretroviral therapy (ART), 5 male children who were born with HIV still maintained undetectable viral loads. Researchers believe that due to innate immunological gender differences, boys might have a better chance of achieving sustained virological remission than girls.
What is the association between the microbiome and autoimmune liver diseases?
<Hepatology Digest>: What role does microbiomics play in the pathogenesis of autoimmune liver diseases? What current research findings have revealed the association between the microbiome and autoimmune liver diseases?
IAS 2023 | Thymosin α1 Therapy for HIV Immunological Non-responders: A Single-arm Clinical Study
As HIV treatment enters the post-ART era, drug side effects and complications have become significant factors affecting the quality of life for patients. Approximately 20% of patients, after 1-2 years of treatment, have viral loads below the detectable limit, but their CD4 cell count remains below normal levels, leading to poorer clinical outcomes.
IAS 2023 | Joining Hands to Eliminate AIDS Epidemic by 2030
On July 23, 2023, the 12th International AIDS Society (IAS) HIV Science Conference, referred to as IAS 2023, officially began in Brisbane, Australia. As one of the largest open academic conferences in the global HIV and AIDS field, the event attracted participation from experts, medical professionals, community groups, and medical enterprises worldwide. The conference emphasized the importance of science as the foundation of policy and practice, highlighting the close integration of science, policy, and activism to promote significant advancements in the HIV and AIDS sector. The theme of the conference is "End Inequalities. End AIDS. End Pandemics.", reflecting IAS's ultimate vision. The goal is to rally health experts globally towards the shared ambition of eradicating AIDS by 2030.
ESMO ASIA 2023 opens, and CSCO accepts certificate of appreciation
ESMO ASIA 2023 inaugurated its opening session, heralding a landmark event in the world of oncology. Hosted in the prestigious Hall 406, this congress brings together the brightest minds in cancer research and treatment, uniting a global community in the fight against this challenging disease. The opening ceremony featured the traditional Dragon Dance, symbolizing prosperity and health. This cultural performance underscored the congress's commitment to diversity and inclusivity, setting a vibrant tone for the event. After the opening address, ESMO also commended society in Asia for their outstanding contributions in promoting international cooperation and exchanges. Dr. Donglu Zhao accepted the certificate of appreciation on behalf of the Chinese Society of Clinical Oncology (CSCO).